|
The Race for Survival in Myelodysplastic Syndromes
|
Sep 2012
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Molecular Pathophysiology of Myelodysplastic Syndromes.
|
Aug 2012
|
Annu Rev Pathol
|
myelodysplastic syndromes (MDS)
|
|
Serial assessment of suspected myelodysplastic syndromes: significance of flow cytometric findings validated by cytomorphology, cytogenetics, and molecular genetics
|
Aug 2012
|
Haematologica
|
myelodysplastic syndromes (MDS)
|
|
Rationale for the Clinical Application of Flow Cytometry in Patients with Myelodysplastic Syndromes
|
Aug 2012
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
Historical perspectives on myelodysplastic syndromes
|
Aug 2012
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes.
|
Aug 2012
|
Blood
|
myelodysplastic syndromes (MDS)
|
|
Under-recognition of Platelet dysfunction in Myelodysplastic Syndromes: are we only seeing the tip of the iceberg?
|
Aug 2012
|
Leuk Lymphoma
|
myelodysplastic syndromes (MDS)
|
|
The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes
|
Aug 2012
|
Leuk Res
|
myelodysplastic syndromes (MDS)
|
|
The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline.
|
Aug 2012
|
Crit Rev Oncol Hematol
|
aplastic anemia
|
|
Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes
|
Aug 2012
|
J Clin Oncol
|
myelodysplastic syndromes (MDS)
|
